Humacyte (HUMA) is scheduled to report Q2 earnings on August 10, 2026. Analysts estimate EPS of $-0.12 and quarterly revenue of $1.14M.
In the most recent quarter (Q1), Humacyte reported EPS of $-0.09, beating estimates of $-0.11 by 0.18%. Revenue came in at $495.00K, missing the estimate of $1.42M by 0.65%.
Over the last 4 quarters, Humacyte has averaged an EPS surprise of 0.23% and a revenue surprise of 0.56%.
Analyze the earnings history of Humacyte using advanced sorting and filters.
The chart below shows Humacyte's reported EPS compared to analyst estimates over recent quarters.
The chart below shows Humacyte's reported revenue compared to analyst estimates over recent quarters.
Humacyte (HUMA) is scheduled to report earnings on August 10, 2026. The last reported earnings were for reported on May 13, 2026 for Q1.
The Actual EPS was $-0.09, which beat the estimate of $-0.11.
The Actual Revenue was $495.00K, which missed the estimate of $1.42M.
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q1 | 2026-05-13 | $-0.09 | $-0.11 | 18.2 % |
| Q4 | 2026-03-27 | $-0.13 | $-0.13 | 0.00 % |
| Q3 | 2025-11-12 | $-0.11 | $-0.16 | 31.3 % |
| Q2 | 2025-08-11 | $-0.24 | $-0.17 | -41.2 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q1 | 2026-05-13 | $495.00K | $1.42M | -65.1 % |
| Q4 | 2026-03-27 | $467.00K | $1.44M | -67.6 % |
| Q3 | 2025-11-12 | $753.00K | $921.70K | -18.3 % |
| Q2 | 2025-08-11 | $301.00K | $1.06M | -71.5 % |